Sakai Yuji, Tsuyuguchi Toshio, Kato Kazuki, Sugiyama Harutoshi, Nishikawa Takao, Takahashi Makoto, Yokosuka Osamu
Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Japan.
Int J Clin Pharmacol Ther. 2013 Jan;51(1):19-25. doi: 10.5414/CP201786.
We investigated the usefulness of doripenem (DRPM), a carbapenem antimicrobial drug, for the treatment of acute cholangitis.
28 patients who received a diagnosis of moderate or severe cholangitis were included in this investigation. 23 patients had moderate cholangitis; 5 patients had severe cholangitis. When moderate or severe cholangitis was diagnosed, administration of DRPM and endoscopic drainage were performed. The dose of DRPM was fixed at 0.5 g, 3 times daily. Evaluation of clinical findings (abdominal pain and body temperature) and blood test findings (WBC, CRP, ALT, ALP, and T-Bil) was performed before and on Day 5 after administration.
Endoscopic drainage was successful in all patients. After administration of DRPM, a significant improvement was observed in all endpoints of both clinical findings and blood test findings (p < 0.05). No adverse events due to administration of DRPM were observed.
It was suggested that administration of DRPM may be clinically useful for the treatment of moderate and severe cholangitis.
我们研究了碳青霉烯类抗菌药物多利培南（DRPM）治疗急性胆管炎的有效性。
本研究纳入了28例被诊断为中度或重度胆管炎的患者。23例患者为中度胆管炎；5例患者为重度胆管炎。诊断为中度或重度胆管炎时，给予DRPM并进行内镜引流。DRPM的剂量固定为0.5 g，每日3次。在给药前和给药后第5天对临床症状（腹痛和体温）和血液检查结果（白细胞、C反应蛋白、谷丙转氨酶、碱性磷酸酶和总胆红素）进行评估。
所有患者内镜引流均成功。给予DRPM后，临床症状和血液检查结果的所有终点指标均有显著改善（p < 0.05）。未观察到因使用DRPM引起的不良事件。
提示使用DRPM可能对中度和重度胆管炎的治疗具有临床实用性。
